Filing Flows › Health Care › Lifevantage (LFVN)
Lifevantage (LFVN) earnings and revenue breakdown
Latest: Q2 2026 · 10-K filed Aug 27, 2026 · Lifevantage (LFVN) Q2 2026 earnings results →
Q2 2026 Revenue down 23% year over year to $42.4M · 3¢ of every $1 of revenue kept as net profit · operating margin 3.9%
Lifevantage made $42.4M in Q2 2026 (-23% Y/Y): Protandim $19.1M, Life Vantage Product Line $9.6M, True Science Product Line $9.0M. Operating margin 3.9%, net earnings $1.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Aug 27, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $42.4M in Q2 2026, down 23% year over year and down 3% from the previous quarter. Protandim was the largest line at 45% of revenue.
Gross margin was 78.0%, down 1.9 points from Q2 2025. Operating profit was $1.7M, a 3.9% margin (unchanged year over year). Operating expenses fell 25% while revenue fell 23%. Net earnings were $1.3M, down 35% year over year. The effective tax rate was 24.6%.
Operating cash flow was $4.8M (up 361% year over year), 373% of net earnings. Non-cash charges added back $697K of depreciation and amortization and $263K of share-based compensation. Working capital and other items added $2.5M. Capital expenditures of $1.0M left free cash flow of $3.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-K | Aug 27, 2026 | $42.4M | -23% | 3.9% | $1.3M | $4.8M |
| Q1 2026 | 10-Q | May 6, 2026 | $43.7M | -25% | 3.8% | $1.4M | $5.0M |
| Q4 2025 | 10-Q | Feb 4, 2026 | $48.9M | -28% | 1.0% | $276K | $2.8M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $47.6M | +0.7% | 4.8% | $2.2M | −$2.3M |
| Q2 2025 | 10-K | Sep 4, 2025 | $55.1M | +13% | 3.9% | $2.0M | $1.0M |
| Q1 2025 | 10-Q | May 6, 2025 | $58.4M | +21% | 6.9% | $3.5M | $2.2M |
| Q4 2024 | 10-Q | Feb 5, 2025 | $67.8M | +31% | 5.1% | $2.5M | $9.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Lifevantage
LifeVantage Corporation (the “Company,” “LifeVantage,” “we,” “us,” or “our”) is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. LifeVantage is dedicated to helping people achieve their health, wellness and financial goals. We provide quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to our independent consultants. We sell our products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, and Singapore. We also sell our products in a number of countries to customers for personal consumption only.
In its own words, from its 10-K, filed Sep 4, 2025.
Lifevantage against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -23% against the peers' median +7%. Operating margin: 3.9% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| LFVN Lifevantage | Q2 2026 | $42.4M | -23% | 3.9% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Lifevantage 10-K on SEC EDGAR · CIK 849146 · Pharmaceutical Preparations
13F: who owns LFVN and who is buying
More on LFVN
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results
- Lifevantage gross margin by quarter
- Lifevantage operating margin by quarter
- Lifevantage net income by quarter
- Lifevantage free cash flow by quarter
- Lifevantage R&D spending by quarter
- Lifevantage capital expenditures by quarter
- Lifevantage Protandim revenue by quarter
- Lifevantage Life Vantage Product Line revenue by quarter
- Lifevantage True Science Product Line revenue by quarter